Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR 1,083.00
+7.00 (0.65%)
Jul 10, 2026, 3:29 PM IST
Strides Pharma Science Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Strides Pharma Science stock has a consensus rating of "Strong Buy" and an average price target of ₹1,339. The average 1-year stock price forecast is 23.61% higher than the current stock price, while the lowest is ₹1,254 (+15.79%) and the highest is ₹1,410 (+30.19%).
Price Target: ₹1,339 (+23.61%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Strides Pharma Science stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
58.23B
from 48.59B
Increased by 19.85%
Revenue Next Year
69.12B
from 58.23B
Increased by 18.71%
EPS This Year
68.15
from 62.84
Increased by 8.45%
EPS Next Year
95.40
from 68.15
Increased by 39.99%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 |
|---|---|---|
| High | 58.5B | |
| Avg | 58.2B | |
| Low | 58.1B |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | 20.5% | |
| Avg | 19.8% | |
| Low | 19.5% |
EPS Forecast
| EPS | 2027 | 2028 |
|---|---|---|
| High | 68.30 | |
| Avg | 68.15 | |
| Low | 68.00 |
EPS Growth
| EPS Growth | 2027 | 2028 |
|---|---|---|
| High | 8.7% | |
| Avg | 8.4% | |
| Low | 8.2% |